High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving PEG-Alpha Interferon
(PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec
(imatinib mesylate) is more effective in treating CML in chronic phase than therapy with
imatinib mesylate alone.